Abstract:Alzheimer’s disease (AD) is a complex heterogeneous neurodegenerative disease that requires an in-depth understanding of its progression pathways and contributing factors to develop effective risk stratification and prevention strategies. In this study, we proposed an outcome-oriented model to identify progression pathways from mild cognitive impairment (MCI) to AD using electronic health records (EHRs) from the OneFlorida+ Clinical Research Consortium. To achieve this, we employed the long short-term memory (LSTM) network to extract relevant information from the sequential records of each patient. The hierarchical agglomerative clustering was then applied to the learned representation to group patients based on their progression subtypes. Our approach identified multiple progression pathways, each of which represented distinct patterns of disease progression from MCI to AD. These pathways can serve as a valuable resource for researchers to understand the factors influencing AD progression and to develop personalized interventions to delay or prevent the onset of the disease.### Competing Interest StatementThe authors have declared no competing interest.### Funding StatementThis work was partially supported by a grant from the Ed and Ethel Moore Alzheimer's Disease Research Program of the Florida Department of Health (FL DOH #23A09) and grants (R01AG080624, R01AG080991, R01AG076234, and UL1TR001427) from the National Institutes of Health (NIH).### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the University of Florida Institutional Review Board (protocol no. IRB202202820).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes

Identification of Endoplasmic Reticulum Stress-Associated Genes and Subtypes for Prediction of Alzheimer’s Disease Based on Interpretable Machine Learning

Identification of immune microenvironment subtypes and signature genes for Alzheimer's disease diagnosis and risk prediction based on explainable machine learning

Identifying the Role of Oligodendrocyte Genes in the Diagnosis of Alzheimer's Disease Through Machine Learning and Bioinformatics Analysis.

Identification of metabolism-related subtypes and feature genes in Alzheimer’s disease

Machine learning identification and immune infiltration of disulfidptosis‐related Alzheimer's disease molecular subtypes

Genes related to neurotransmitter receptors as potential biomarkers for Alzheimer's disease

Identification of Outcome-Oriented Progression Subtypes from Mild Cognitive Impairment to Alzheimer’s Disease Using Electronic Health Records

Identification of Diagnostic Biomarkers in Alzheimer's Disease by Integrated Bioinformatic Analysis and Machine Learning Strategies.

Identification and prediction of m7G-related Alzheimer's disease subtypes: insights from immune infiltration and machine learning models

Uncovering the Impact of Aggrephagy in the Development of Alzheimer's Disease: Insights Into Diagnostic and Therapeutic Approaches from Machine Learning Analysis

Identification of diagnostic signatures associated with immune infiltration in Alzheimer's disease by integrating bioinformatic analysis and machine-learning strategies

hdWGCNA and Cellular Communication Identify Active NK Cell Subtypes in Alzheimer's Disease and Screen for Diagnostic Markers through Machine Learning

Identification of diagnostic genes for both Alzheimer's disease and Metabolic syndrome by the machine learning algorithm

Identification of Immune Cells and Key Genes associated with Alzheimer's Disease

Identification of genes related to glucose metabolism and analysis of the immune characteristics in Alzheimer's disease

Related Genes and Potential Biomarkers for Early Diagnosis of Alzheimer’s Disease

Identification of biomarkers of Alzheimer's disease and their characterization of immune function

Identification of diagnostic gene signatures and molecular mechanisms for non-alcoholic fatty liver disease and Alzheimer's disease through machine learning algorithms

Machine learning prediction and tau-based screening identifies potential Alzheimer’s disease genes relevant to immunity

Identification of disulfidptosis-related genes and subgroups in Alzheimer's disease

Characterizing the clinical heterogeneity of early symptomatic Alzheimer's disease: a data-driven machine learning approach